| Market Capitalization (Millions $) |
3 |
| Shares
Outstanding (Millions) |
7 |
| Employees |
10 |
| Revenues (TTM) (Millions $) |
5 |
| Net Income (TTM) (Millions $) |
-12 |
| Cash Flow (TTM) (Millions $) |
-2 |
| Capital Exp. (TTM) (Millions $) |
0 |
Business Description
Ensysce Biosciences Inc is a biopharmaceutical company that focuses on developing novel drug delivery technologies and formulations. The company aims to address various challenges in the pharmaceutical industry, such as improving the bioavailability and efficacy of drugs, reducing side effects, and enhancing patient compliance.
Ensysce Biosciences utilizes its proprietary technology platforms to enhance the delivery of both small molecule drugs and large molecules, such as peptides and proteins. Their technologies include platforms like DuraGel and DuraSorb, which enable sustained and controlled release of drugs over an extended period of time.
The company's innovative drug delivery systems have the potential to revolutionize the treatment of various diseases, including pain management, addiction, cancer, and central nervous system disorders. With a focus on improving patient outcomes and quality of life, Ensysce Biosciences is constantly striving to develop safer, more effective, and convenient drug delivery solutions.
Company Address: 7946 Ivanhoe Avenue La Jolla 92037 CA
Company Phone Number: 263-4196 Stock Exchange / Ticker: NASDAQ ENSC
|
19.3% 
221.12 %